Search

Your search keyword '"Vidailhet, M."' showing total 1,481 results
Start Over Author "Vidailhet, M."
1,481 results on '"Vidailhet, M."'

151. La consommation des glucides chez l'enfant et l'adolescent

Author

Frelut, M. L., Bocquet, A., Bresson, J. L., Briend, André, Chouraqui, J. P., Darmaun, D., Dupont, C., Ghisolfi, J., Girardet, J. P., Goulet, O., Putet, G., Rieu, D., Rigo, J., Turck, D., and Vidailhet, M.

Subjects
obesity, child, dietary carbohydrates, energy intake, adolescents, food policy
Published
2006

155. The pleiotropic movement disorders phenotype of adult ataxia-telangiectasia

Author

Meneret, A., primary, Ahmar-Beaugendre, Y., additional, Rieunier, G., additional, Mahlaoui, N., additional, Gaymard, B., additional, Apartis, E., additional, Tranchant, C., additional, Rivaud-Pechoux, S., additional, Degos, B., additional, Benyahia, B., additional, Suarez, F., additional, Maisonobe, T., additional, Koenig, M., additional, Durr, A., additional, Stern, M.-H., additional, Dubois d'Enghien, C., additional, Fischer, A., additional, Vidailhet, M., additional, Stoppa-Lyonnet, D., additional, Grabli, D., additional, and Anheim, M., additional

Published
2014
Full Text
View/download PDF

158. Congenital mirror movements: Mutational analysis of RAD51 and DCC in 26 cases

Author

Meneret, A., primary, Depienne, C., additional, Riant, F., additional, Trouillard, O., additional, Bouteiller, D., additional, Cincotta, M., additional, Bitoun, P., additional, Wickert, J., additional, Lagroua, I., additional, Westenberger, A., additional, Borgheresi, A., additional, Doummar, D., additional, Romano, M., additional, Rossi, S., additional, Defebvre, L., additional, De Meirleir, L., additional, Espay, A. J., additional, Fiori, S., additional, Klebe, S., additional, Quelin, C., additional, Rudnik-Schoneborn, S., additional, Plessis, G., additional, Dale, R. C., additional, Sklower Brooks, S., additional, Dziezyc, K., additional, Pollak, P., additional, Golmard, J.-L., additional, Vidailhet, M., additional, Brice, A., additional, and Roze, E., additional

Published
2014
Full Text
View/download PDF

159. Lipid intake in children under 3years of age in France. A position paper by the Committee on Nutrition of the French Society of Paediatrics

Author

Briend, A., primary, Legrand, P., additional, Bocquet, A., additional, Girardet, J.-P., additional, Bresson, J.-L., additional, Chouraqui, J.-P., additional, Darmaun, D., additional, Dupont, C., additional, Frelut, M.L., additional, Goulet, O., additional, Hankard, R., additional, Rieu, D., additional, Simeoni, U., additional, Turck, D., additional, and Vidailhet, M., additional

Published
2014
Full Text
View/download PDF

160. Optimal target localization for subthalamic stimulation in patients with Parkinson disease

Author

Welter, M.-L., primary, Schupbach, M., additional, Czernecki, V., additional, Karachi, C., additional, Fernandez-Vidal, S., additional, Golmard, J.-L., additional, Serra, G., additional, Navarro, S., additional, Welaratne, A., additional, Hartmann, A., additional, Mesnage, V., additional, Pineau, F., additional, Cornu, P., additional, Pidoux, B., additional, Worbe, Y., additional, Zikos, P., additional, Grabli, D., additional, Galanaud, D., additional, Bonnet, A.-M., additional, Belaid, H., additional, Dormont, D., additional, Vidailhet, M., additional, Mallet, L., additional, Houeto, J.-L., additional, Bardinet, E., additional, Yelnik, J., additional, and Agid, Y., additional

Published
2014
Full Text
View/download PDF

163. How much phenotypic variation can be attributed to parkin genotype?

Author

Lohmann, E., Periquet, M., Bonifati, V., Wood, N.W., Michele, G. de, Bonnet, A.M., Fraix, V., Brousolle, E., Horstink, M.W.I.M., Vidailhet, M., Verpillat, P., Gasser, T., Nicholl, D., Teive, H., Raskin, S., Rascol, O., Destee, A., Ruberg, M., Gasparini, F., Meco, G., Agid, Y., Durr, A., and Brice, A.

Subjects
Adult, Aged, 80 and over, Male, Heterozygote, Adolescent, Genotype, Ubiquitin-Protein Ligases, Mutation, Missense, Genetic Variation, Parkinson Disease, Exons, Middle Aged, nervous system diseases, Antiparkinson Agents, Levodopa, Phenotype, Cognitive neurosciences [UMCN 3.2], Mutation, Disease Progression, Humans, Female, Age of Onset, Aged
Abstract

Item does not contain fulltext To establish phenotype-genotype correlations in early-onset parkinsonism, we have compared the phenotype of a large series of 146 patients with and 250 patients without parkin mutations. Although no single sign distinguished the groups, patients with mutations had significantly earlier and more symmetrical onset, dystonia more often at onset and hyperreflexia, slower progression of the disease, and a tendency toward a greater response to levodopa despite lower doses. After forward stepwise multiple logistic regression analysis, dystonia at onset and brisk reflexes were not longer significantly different but were correlated with age at onset rather than the presence of the parkin mutation. Age at onset in carriers of parkin mutations varied as did the rate of progression of the disease: the younger the age at onset the slower the evolution. The genotype influenced the phenotype: carriers of at least one missense mutation had a higher United Parkinson's Disease Rating Scale motor score than those carrying two truncating mutations. The localization of the mutations was also important because missense mutations in functional domains of parkin resulted in earlier onset. Patients with a single heterozygous mutation had significantly later and more asymmetrical onset and more frequent levodopa-induced fluctuations and dystonia than patients with two mutations.

Published
2003

164. The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism

Author

Klebe, S., Golmard, J.L., Nalls, M.A., Saad, M., Singleton, A.B., Bras, J.M., Hardy, J., Simon-Sanchez, J., Heutink, P., Kuhlenbaumer, G., Charfi, R., Klein, C., Hagenah, J., Gasser, T., Wurster, I., Lesage, S., Lorenz, D., Deuschl, G., Durif, F., Pollak, P., Damier, P., Tison, F., Durr, A., Amouyel, P., Lambert, J.C., Tzourio, C., Maubaret, C., Charbonnier-Beaupel, F., Tahiri, K., Vidailhet, M., Martinez, M., Brice, A., Corvol, J.C., Bloem, B.R., Post, B., Scheffer, H., Warrenburg, B.P.C. van de, et al., Klebe, S., Golmard, J.L., Nalls, M.A., Saad, M., Singleton, A.B., Bras, J.M., Hardy, J., Simon-Sanchez, J., Heutink, P., Kuhlenbaumer, G., Charfi, R., Klein, C., Hagenah, J., Gasser, T., Wurster, I., Lesage, S., Lorenz, D., Deuschl, G., Durif, F., Pollak, P., Damier, P., Tison, F., Durr, A., Amouyel, P., Lambert, J.C., Tzourio, C., Maubaret, C., Charbonnier-Beaupel, F., Tahiri, K., Vidailhet, M., Martinez, M., Brice, A., Corvol, J.C., Bloem, B.R., Post, B., Scheffer, H., Warrenburg, B.P.C. van de, and et al.

Abstract

Item does not contain fulltext, The catechol-O-methyltranferase (COMT) is one of the main enzymes that metabolise dopamine in the brain. The Val158Met polymorphism in the COMT gene (rs4680) causes a trimodal distribution of high (Val/Val), intermediate (Val/Met) and low (Met/Met) enzyme activity. We tested whether the Val158Met polymorphism is a modifier of the age at onset (AAO) in Parkinson's disease (PD). The rs4680 was genotyped in a total of 16 609 subjects from five independent cohorts of European and North American origin (5886 patients with PD and 10 723 healthy controls). The multivariate analysis for comparing PD and control groups was based on a stepwise logistic regression, with gender, age and cohort origin included in the initial model. The multivariate analysis of the AAO was a mixed linear model, with COMT genotype and gender considered as fixed effects and cohort and cohort-gender interaction as random effects. COMT genotype was coded as a quantitative variable, assuming a codominant genetic effect. The distribution of the COMT polymorphism was not significantly different in patients and controls (p=0.22). The Val allele had a significant effect on the AAO with a younger AAO in patients with the Val/Val (57.1+/-13.9, p=0.03) than the Val/Met (57.4+/-13.9) and the Met/Met genotypes (58.3+/-13.5). The difference was greater in men (1.9 years between Val/Val and Met/Met, p=0.007) than in women (0.2 years, p=0.81). Thus, the Val158Met COMT polymorphism is not associated with PD in the Caucasian population but acts as a modifier of the AAO in PD with a sexual dimorphism: the Val allele is associated with a younger AAO in men with idiopathic PD.

Published
2013

165. The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism

Author

Klebe, S, Golmard, JL, Nalls, MA, Saad, M, Singleton, AB, Bras, JM, Hardy, J, Simon-Sanchez, J, Heutink, P, Kuhlenbaumer, G, Charfi, R, Klein, C, Hagenah, J, Gasser, T, Wurster, I, Lesage, S, Lorenz, D, Deuschl, G, Durif, F, Pollak, P, Damier, P, Tison, F, Durr, A, Amouyel, P, Lambert, JC, Tzourio, C, Maubaret, C, Charbonnier-Beaupel, F, Tahiri, K (Khadija), Vidailhet, M, Martinez, M, Brice, A, Corvol, JC, Klebe, S, Golmard, JL, Nalls, MA, Saad, M, Singleton, AB, Bras, JM, Hardy, J, Simon-Sanchez, J, Heutink, P, Kuhlenbaumer, G, Charfi, R, Klein, C, Hagenah, J, Gasser, T, Wurster, I, Lesage, S, Lorenz, D, Deuschl, G, Durif, F, Pollak, P, Damier, P, Tison, F, Durr, A, Amouyel, P, Lambert, JC, Tzourio, C, Maubaret, C, Charbonnier-Beaupel, F, Tahiri, K (Khadija), Vidailhet, M, Martinez, M, Brice, A, and Corvol, JC

Published
2013

166. Dystonia rating scales: critique and recommendations

Author

Albanese, Alberto, Del Sorbo, Francesca, Comella, C, Jinnah, Ha, Mink, Jw, Post, B, Vidailhet, M, Volkmann, J, Warner, Tt, Leentjens, Afg, Martinez Martin, P, Stebbins, Gt, Goetz, Cg, Schrag, A., Albanese, Alberto (ORCID:0000-0002-5864-0006), Albanese, Alberto, Del Sorbo, Francesca, Comella, C, Jinnah, Ha, Mink, Jw, Post, B, Vidailhet, M, Volkmann, J, Warner, Tt, Leentjens, Afg, Martinez Martin, P, Stebbins, Gt, Goetz, Cg, Schrag, A., and Albanese, Alberto (ORCID:0000-0002-5864-0006)

Abstract

Many rating scales have been applied to the evaluation of dystonia, but only few have been assessed for clinimetric properties. The Movement Disorders Society commissioned this task force to critique existing dystonia rating scales and place them in the clinical and clinimetric context. A systematic literature review was conducted to identify rating scales that have either been validated or used in dystonia. Thirty-six potential scales were identified. Eight were excluded because they did not meet review criteria, leaving 28 scales that were critiqued and rated by the task force. Seven scales were found to meet criteria to be "recommended": the Blepharospasm Disability Index is recommended for rating blepharospasm; the Cervical Dystonia Impact Scale and the Toronto Western Spasmodic Torticollis Rating Scale for rating cervical dystonia; the Craniocervical Dystonia Questionnaire for blepharospasm and cervical dystonia; the Voice Handicap Index (VHI) and the Vocal Performance Questionnaire (VPQ) for laryngeal dystonia; and the Fahn-Marsden Dystonia Rating Scale for rating generalized dystonia. Two "recommended" scales (VHI and VPQ) are generic scales validated on few patients with laryngeal dystonia, whereas the others are disease-specific scales. Twelve scales met criteria for "suggested" and 7 scales met criteria for "listed." All the scales are individually reviewed in the online information. The task force recommends 5 specific dystonia scales and suggests to further validate 2 recommended generic voice-disorder scales in dystonia. Existing scales for oromandibular, arm, and task-specific dystonia should be refined and fully assessed. Scales should be developed for body regions for which no scales are available, such as lower limbs and trunk.

Published
2013

167. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.

Author

Moreau, C., Delval, A., Defebvre, L., Dujardin, K., Duhamel, A., Petyt, G., Vuillaume, I., Corvol, J.C., Brefel-Courbon, C., Ory-Magne, F., Guehl, D., Eusebio, A., Fraix, V., Saulnier, P.J., Lagha-Boukbiza, O., Durif, F., Faighel, M., Giordana, C., Drapier, S., Maltete, D., Tranchant, C., Houeto, J.L., Debû, B.H.G., Sablonniere, B., Azulay, J.P., Tison, F., Rascol, O., Vidailhet, M., Destee, A., Bloem, B.R., Bordet, R., Devos, D., Moreau, C., Delval, A., Defebvre, L., Dujardin, K., Duhamel, A., Petyt, G., Vuillaume, I., Corvol, J.C., Brefel-Courbon, C., Ory-Magne, F., Guehl, D., Eusebio, A., Fraix, V., Saulnier, P.J., Lagha-Boukbiza, O., Durif, F., Faighel, M., Giordana, C., Drapier, S., Maltete, D., Tranchant, C., Houeto, J.L., Debû, B.H.G., Sablonniere, B., Azulay, J.P., Tison, F., Rascol, O., Vidailhet, M., Destee, A., Bloem, B.R., Bordet, R., and Devos, D.

Abstract

1 juli 2012, Item does not contain fulltext, BACKGROUND: Despite optimum medical management, many patients with Parkinson's disease are incapacitated by gait disorders including freezing of gait. We aimed to assess whether methylphenidate--through its combined action on dopamine and noradrenaline reuptake--would improve gait disorders and freezing of gate in patients with advanced Parkinson's disease without dementia who also received subthalamic nucleus stimulation. METHODS: This multicentre, parallel, double-blind, placebo-controlled, randomised trial was done in 13 movement disorders departments in France between October, 2009, and December, 2011. Eligible patients were younger than 80 years and had Parkinson's disease, severe gait disorders, and freezing of gate despite optimised treatment of motor fluctuations with dopaminergic drugs and subthalamic stimulation. We randomly assigned patients (1:1 with a computer random-number generator in blocks of four) to receive methylphenidate (1 mg/kg per day) or placebo capsules for 90 days. Patients, their carers, study staff, investigators, and data analysts were masked to treatment allocation. To control for confounding effects of levodopa we assessed patients under standardised conditions with an acute levodopa challenge. Our primary outcome was a change in the number of steps during the stand-walk-sit (SWS) test without levodopa. We compared the respective mean numbers of steps at day 90 in the methylphenidate and placebo groups in a covariance analysis and adjusted for baseline differences. This trial is registered with ClinicalTrials.gov, number NCT00914095. FINDINGS: We screened 81 patients and randomly assigned 35 to receive methylphenidate and 34 to receive placebo. 33 patients in the methylphenidate group and 32 patients in the placebo group completed the study. Efficacy outcomes were assessed in the patients who completed the study. Compared with patients in the placebo group (median 33 steps [IQR 26-45]), the patients in the methylphenidate group made f

Published
2012

168. Comité de rédaction

Author

Béjot, Y., Créange, A., Defebvre, L., Mazighi, M., Alamowitch, S., Anheim, M., Arnulf, I., Attal, N., Azulay, P., Behin, A., Bourdillon, P., Bourgin, P., Brochet, B., Calvière, L., Ceccaldi, M., Clavelou, P., Corcia, P., Cordonnier, C., Debouverie, M., Delorme, T., Denier, C., Detante, O., de Sèze, J., Ducros, A., Dumurgier, J., Eusebio, A., Félician, O., Froment, C., Grabli, D., Hoang-Xuan, K., Jonas, J., Krystkowiak, P., Laforêt, P., Lamirel, C., Lannuzel, A., Laplaud, D., Lavallée, P., Lebouvier, T., Lévy, R., Magy, L., Maillard, L., Maltête, D., Martinaud, O., Meissner, W., Moreau, C., Moreau, T., Nicolas, G., Nizard, J., Olivot, J.-M., Peter-Derex, L., Pico, F., Pouget, J., Proust, F., Rheims, S., Ricard, D., Ruppert, E., Sharshar, T., Sibon, I., Thobois, S., Timsit, S., Touzé, E., Tranchant, C., Turc, G., Tyvaert, L., Verny, C., Viala, F., Vidailhet, M., Vighetto, A., Vukusic, S., Wolff, V., Zephir, H., Zuber, M., Camdessanché, J.-P., Flamand-Roze, E., Labauge, P., Moro, E., and Nasr, N.

Published
2021
Full Text
View/download PDF

169. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.

Author

Bensimon, G, Ludolph, A, Agid, Y, Vidailhet, M, Payan, C, Leigh, PN, NNIPPS Study Group, Bensimon, G, Ludolph, A, Agid, Y, Vidailhet, M, Payan, C, Leigh, PN, and NNIPPS Study Group

Abstract

Parkinson plus diseases, comprising mainly progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are rare neurodegenerative conditions. We designed a double-blind randomized placebo-controlled trial of riluzole as a potential disease-modifying agent in Parkinson plus disorders (NNIPPS: Neuroprotection and Natural History in Parkinson Plus Syndromes). We analysed the accuracy of our clinical diagnostic criteria, and studied prognostic factors for survival. Patients with an akinetic-rigid syndrome diagnosed as having PSP or MSA according to modified consensus diagnostic criteria were considered for inclusion. The psychometric validity (convergent and predictive) of the NNIPPS diagnostic criteria were tested prospectively by clinical and pathological assessments. The study was powered to detect a 40% decrease in relative risk of death within PSP or MSA strata. Patients were randomized to riluzole or matched placebo daily and followed up to 36 months. The primary endpoint was survival. Secondary efficacy outcomes were rates of disease progression assessed by functional measures. A total of 767 patients were randomized and 760 qualified for the Intent to Treat (ITT) analysis, stratified at entry as PSP (362 patients) or MSA (398 patients). Median follow-up was 1095 days (range 249-1095). During the study, 342 patients died and 112 brains were examined for pathology. NNIPPS diagnostic criteria showed for both PSP and MSA excellent convergent validity with the investigators' assessment of diagnostic probability (point-biserial correlation: MSA r(pb) = 0.93, P < 0.0001; PSP, r(pb) = 0.95, P < 0.0001), and excellent predictive validity against histopathology [sensitivity and specificity (95% CI) for PSP 0.95 (0.88-0.98) and 0.84 (0.77-0.87); and for MSA 0.96 (0.88-0.99) and 0.91 (0.86-0.93)]. There was no evidence of a drug effect on survival in the PSP or MSA strata (3 year Kaplan-Meier estimates PSP-riluzole: 0.51, PSP-placebo: 0.50; MSA-riluzole: 0.53, MS

Published
2009

170. [Study of cortical atrophy with magnetic resonance imaging in corticobasal degeneration]

Author

Ballan G, Tison F, VINCENT DOUSSET, Vidailhet M, Agid Y, and Henry P

Subjects
Cerebral Cortex, Male, Tomography, Emission-Computed, Single-Photon, Nerve Degeneration, Humans, Female, Neurodegenerative Diseases, Age of Onset, Middle Aged, Magnetic Resonance Imaging, Aged, Retrospective Studies, Tomography, Emission-Computed
Abstract

Corticobasal degeneration (C.B.D.) is a neurodegenerative disorder characterized mainly by an asymmetrical a kineto-rigid syndrome associated with fronto-parietal cortical signs, particularly apraxia. Conventional imaging even magnetic resonance imaging (M.R.I.) has often been considered as poorly contributive for the diagnosis of C.B.D. We retrospectively studied routinely performed M.R.I. scans of 15 patients presenting a clinical and metabolic (P.E.T/S.P.E.C.T.) syndrome characteristic of probable C.B.D. M.R.I. scans were assessed by 3 investigators, not aware of the clinically most affected side, taking into account M.R.I. technical parameters. We quantified, on each side, the cortical atrophy (frontal, parietal and temporal) and the white matter changes, by using the semi-quantified method of Victoroff et al. (1994). Abnormalities were considered if observed by at least 2 of the 3 investigators. Abnormalities were then correlated with the side initially and most severely affected. The most contributive findings were the asymmetric parietal atrophy (clinically correlated in 93 p. 100 of cases), asymmetric frontal atrophy (clinically correlated in 60 p. 100) and asymmetric dilatation of the lateral ventricles (clinically correlated in 60 p. 100). 80 p. 100 of affected subjects displayed at least 2 of these M.R.I. abnormalities. These results are in accordance with the metabolic and pathologic features of C.B.D. This study demonstrates that M.R.I. evaluation of the cortical atrophy asymmetry may contribute to the diagnosis of C.B.D.

Published
1998

171. Somatotopical organization of striatal activation during finger and toe movement: a 3-T functional magnetic resonance imaging study

Author

Lehéricy, Stéphane, van de Moortele, P. F., Lobel, E., Paradis, A. L., Vidailhet, M., Frouin, V., Neveu, P., Agid, Y., Marsault, C., Le Bihan, D., IFR de Neuroimagerie Fonctionnelle (IFR 49), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Neuro-anatomie fonctionnelle du comportement et de ses troubles, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR70-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Neuro-Imagerie de Recherche (CENIR), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire de Physiologie de la Perception et de l'Action (LPPA), Collège de France (CdF (institution))-Centre National de la Recherche Scientifique (CNRS), Université du Québec à Montréal = University of Québec in Montréal (UQAM), Service de Génétique Cytogénétique et Embryologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Service de neurologie [Saint-Antoine], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CEA : DSV/iRCM/SCSR/LEFG (LEFG), Laboratoire d'Exploration Fonctionnelle des Génomes (LEFG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7), Processus d'Activation Sélective par Transfert d'Energie Uni-électronique ou Radiatif (UMR 8640) (PASTEUR), Université Pierre et Marie Curie - Paris 6 (UPMC)-Département de Chimie - ENS Paris, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physique Statistique de l'ENS (LPS), Université Paris Diderot - Paris 7 (UPD7)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS)-Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Neurologie et thérapeutique expérimentale, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR70-Université Pierre et Marie Curie - Paris 6 (UPMC), Service Hospitalier Frédéric Joliot (SHFJ), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Service NEUROSPIN (NEUROSPIN), Center for NeuroImaging Research-Human MRI Neuroimaging core facility for clinical research [ICM Paris] (CENIR), Institut du Cerveau = Paris Brain Institute (ICM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Fédération de recherche du Département de physique de l'Ecole Normale Supérieure - ENS Paris (FRDPENS), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Laboratoire de physiologie de la perception et de l'action (LPPA), Collège de France (CdF)-Centre National de la Recherche Scientifique (CNRS), Université du Québec à Montréal (UQAM), Service de neurologie 1 [CHU Pitié-Salpétrière], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], École normale supérieure - Paris (ENS Paris)-École normale supérieure - Paris (ENS Paris)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Adult, Male, Brain Mapping, MESH: Humans, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, Movement, MESH: Adult, MESH: Psychomotor Performance, MESH: Movement, Toes, Magnetic Resonance Imaging, Basal Ganglia, Corpus Striatum, MESH: Male, MESH: Toes, MESH: Corpus Striatum, MESH: Magnetic Resonance Imaging, Fingers, MESH: Basal Ganglia, MESH: Fingers, Humans, Female, MESH: Female, Psychomotor Performance, MESH: Brain Mapping
Abstract

International audience; The present study aimed at determining the distribution and somatotopical organization of striatal activation during performance of simple motor tasks. Ten right-handed healthy volunteers were studied by using a 3-T whole-body magnetic resonance unit and echo planar imaging. The tasks consisted of self-paced flexion/extension of the right fingers or toes. Motor activation was found mainly in the putamen posterior to the anterior commissure (10 of 10 subjects) and the globus pallidus (6 subjects), whereas the caudate nucleus was activated in only 3 subjects, and in a smaller area. Thus, performance of a simple motor task activated the sensorimotor territory of the basal ganglia. Within the putamen, there was a somatotopical organization of the foot and hand areas similar to that observed in nonhuman primates. These data suggest that functional magnetic resonance imaging can be used to study normal function of the basal ganglia and should therefore also allow investigation of patients with movement disorders.

Published
1998
Full Text
View/download PDF

172. Motor cortex stimulation does not improve dystonia secondary to a focal basal ganglia lesion

Author

Rieu, I., primary, Aya Kombo, M., additional, Thobois, S., additional, Derost, P., additional, Pollak, P., additional, Xie, J., additional, Pereira, B., additional, Vidailhet, M., additional, Burbaud, P., additional, Lefaucheur, J. P., additional, Lemaire, J. J., additional, Mertens, P., additional, Chabardes, S., additional, Broussolle, E., additional, and Durif, F., additional

Published
2013
Full Text
View/download PDF

174. High COMT activity is associated with earlier age at onset in PD

Author

Klebe, S., primary, Golmard, J., additional, Charfi, R., additional, Kuhlenbäumer, G., additional, Klein, C., additional, Hagenah, J., additional, Gasser, T., additional, Wurster, I., additional, Lessage, S., additional, Lorenz, D., additional, Deuschl, G., additional, Saad, M., additional, Martinez, M., additional, Durif, F., additional, Pollak, P., additional, Damier, P., additional, Tison, F., additional, Durr, A., additional, Amouyel, P., additional, Lambert, J., additional, Tzourio, C., additional, Maubert, C., additional, Charbonnier-Beaupel, F., additional, Tahiri, K., additional, Vidailhet, M., additional, Brice, A., additional, and Corvol, J., additional

Published
2013
Full Text
View/download PDF

177. Criteria for the diagnosis of corticobasal degeneration

Author

Armstrong, M. J., primary, Litvan, I., additional, Lang, A. E., additional, Bak, T. H., additional, Bhatia, K. P., additional, Borroni, B., additional, Boxer, A. L., additional, Dickson, D. W., additional, Grossman, M., additional, Hallett, M., additional, Josephs, K. A., additional, Kertesz, A., additional, Lee, S. E., additional, Miller, B. L., additional, Reich, S. G., additional, Riley, D. E., additional, Tolosa, E., additional, Troster, A. I., additional, Vidailhet, M., additional, and Weiner, W. J., additional

Published
2013
Full Text
View/download PDF

179. FXTAS: New insights and the need for revised diagnostic criteria

Author

Apartis, E., primary, Blancher, A., additional, Meissner, W. G., additional, Guyant-Marechal, L., additional, Maltete, D., additional, De Broucker, T., additional, Legrand, A.-P., additional, Bouzenada, H., additional, Thanh, H. T., additional, Sallansonnet-Froment, M., additional, Wang, A., additional, Tison, F., additional, Roue-Jagot, C., additional, Sedel, F., additional, Charles, P., additional, Whalen, S., additional, Heron, D., additional, Thobois, S., additional, Poisson, A., additional, Lesca, G., additional, Ouvrard-Hernandez, A.-M., additional, Fraix, V., additional, Palfi, S., additional, Habert, M.-O., additional, Gaymard, B., additional, Dussaule, J.-C., additional, Pollak, P., additional, Vidailhet, M., additional, Durr, A., additional, Barbot, J.-C., additional, Gourlet, V., additional, Brice, A., additional, and Anheim, M., additional

Published
2012
Full Text
View/download PDF

182. Large-scale replication and heterogeneity in Parkinson disease genetic loci

Author

Sharma, Manu, primary, Ioannidis, John P.A., additional, Aasly, Jan O., additional, Annesi, Grazia, additional, Brice, Alexis, additional, Van Broeckhoven, Christine, additional, Bertram, Lars, additional, Bozi, Maria, additional, Crosiers, David, additional, Clarke, Carl, additional, Facheris, Maurizio, additional, Farrer, Matthew, additional, Garraux, Gaetan, additional, Gispert, Suzana, additional, Auburger, Georg, additional, Vilariño-Güell, Carles, additional, Hadjigeorgiou, Georgios M., additional, Hicks, Andrew A., additional, Hattori, Nobutaka, additional, Jeon, Beom, additional, Lesage, Suzanne, additional, Lill, Christina M., additional, Lin, Juei-Jueng, additional, Lynch, Timothy, additional, Lichtner, Peter, additional, Lang, Anthony E., additional, Mok, Vincent, additional, Jasinska-Myga, Barbara, additional, Mellick, George D., additional, Morrison, Karen E., additional, Opala, Grzegorz, additional, Pramstaller, Peter P., additional, Pichler, Irene, additional, Park, Sung Sup, additional, Quattrone, Aldo, additional, Rogaeva, Ekaterina, additional, Ross, Owen A., additional, Stefanis, Leonidas, additional, Stockton, Joanne D., additional, Satake, Wataru, additional, Silburn, Peter A., additional, Theuns, Jessie, additional, Tan, Eng-King, additional, Toda, Tatsushi, additional, Tomiyama, Hiroyuki, additional, Uitti, Ryan J., additional, Wirdefeldt, Karin, additional, Wszolek, Zbigniew, additional, Xiromerisiou, Georgia, additional, Yueh, Kuo-Chu, additional, Zhao, Yi, additional, Gasser, Thomas, additional, Maraganore, Demetrius, additional, Krüger, Rejko, additional, Boyle, R.S, additional, Sellbach, A, additional, O'Sullivan, J.D., additional, Sutherland, G.T., additional, Siebert, G.A, additional, Dissanayaka, N.N.W, additional, Pickut, Barbara, additional, Engelborghs, Sebastiaan, additional, Meeus, Bram, additional, De Deyn, Peter P., additional, Cras, Patrick, additional, Lang, Anthony E, additional, Agid, Y, additional, Anheim, M, additional, Bonnet, A-M, additional, Borg, M, additional, Brice, A, additional, Broussolle, E, additional, Corvol, JC, additional, Damier, P, additional, Destée, A, additional, Dürr, A, additional, Durif, F, additional, Lesage, S, additional, Lohmann, E, additional, Pollak, P, additional, Rascol, O, additional, Tison, F, additional, Tranchant, C, additional, Viallet, F, additional, Vidailhet, M, additional, Tzourio, Christophe, additional, Amouyel, Philippe, additional, Loriot, Marie-Anne, additional, Mutez, Eugénie, additional, Duflot, Aurélie, additional, Legendre, Jean-Philippe, additional, Waucquier, Nawal, additional, Riess, Olaf, additional, Berg, Daniela, additional, Schulte, Claudia, additional, Klein, Christine, additional, Djarmati, Ana, additional, Hagenah, Johann, additional, Lohmann, Katja, additional, Hilker, Rüdiger, additional, van de Loo, Simone, additional, Dardiotis, Efthimios, additional, Tsimourtou, Vaia, additional, Ralli, Styliani, additional, Kountra, Persa, additional, Patramani, Gianna, additional, Vogiatzi, Cristina, additional, Funayama, Manabu, additional, Yoshino, Hiroyo, additional, Li, Yuanzhe, additional, Imamichi, Yoko, additional, Lynch, Tim, additional, Gibson, J. Mark, additional, Valente, Enza Maria, additional, Ferraris, Alessandro, additional, Dallapiccola, Bruno, additional, Ialongo, Tamara, additional, Brighina, Laura, additional, Corradi, Barbara, additional, Piolti, Roberto, additional, Tarantino, Patrizia, additional, Annesi, Ferdinanda, additional, Jeon, Beom S., additional, Park, Sung-Sup, additional, Aasly, J, additional, Klodowska-Duda, Gabriela, additional, Boczarska-Jedynak, Magdalena, additional, Tan, Eng King, additional, Belin, Andrea Carmine, additional, Olson, Lars, additional, Galter, Dagmar, additional, Westerlund, Marie, additional, Sydow, Olof, additional, Nilsson, Christer, additional, Puschmann, Andreas, additional, Lin, JJ, additional, Maraganore, Demetrius M., additional, Ahlskog, J, Eric, additional, de Andrade, Mariza, additional, Lesnick, Timothy G., additional, Rocca, Walter A., additional, Checkoway, Harvey, additional, Ross, Owen A, additional, and Wszolek, Zbigniew K., additional

Published
2012
Full Text
View/download PDF

183. Why Does Bilateral Subthalamic Stimulation Induced Cognitive Decline in Patients with Parkinson's Disease? (S52.005)

Author

Welter, M.-L., primary, Czernecki, V., additional, Schupbach, M., additional, Fernandez-Vidal, S., additional, Karachi, C., additional, Navarro, S., additional, Cornu, P., additional, Pidoux, B., additional, Mallet, L., additional, Dormont, D., additional, Vidailhet, M., additional, Grabli, D., additional, Bonnet, A.-M., additional, Belaid, H., additional, Houeto, J.-L., additional, Bardinet, E., additional, Yelnik, J., additional, and Agid, Y., additional

Published
2012
Full Text
View/download PDF

184. Why Does Bilateral Subthalamic Stimulation Induced Cognitive Decline in Patients with Parkinson's Disease? (IN6-2.001)

Author

Welter, M.-L., primary, Czernecki, V., additional, Schupbach, M., additional, Fernandez-Vidal, S., additional, Karachi, C., additional, Navarro, S., additional, Cornu, P., additional, Pidoux, B., additional, Mallet, L., additional, Dormont, D., additional, Vidailhet, M., additional, Grabli, D., additional, Bonnet, A.-M., additional, Belaid, H., additional, Houeto, J.-L., additional, Bardinet, E., additional, Yelnik, J., additional, and Agid, Y., additional

Published
2012
Full Text
View/download PDF

188. Amélioration du mouvement et de la parole pendant les troubles du comportement en sommeil paradoxal au cours de l’atrophie multi systématisée

Author

Cochen De Cock, V., primary, Debs, R., additional, Oudiette, D., additional, Leu, S., additional, Radgi, F., additional, Tiberge, M., additional, Yu, H., additional, Bayard, S., additional, Roze, E., additional, Vidailhet, M., additional, Dauvilliers, Y., additional, Rascol, O., additional, and Arnulf, I., additional

Published
2012
Full Text
View/download PDF

190. Dietary treatment of cows' milk protein allergy in childhood: a commentary by the Committee on Nutrition of the French Society of Paediatrics

Author

Dupont, C., primary, Chouraqui, J. P., additional, de Boissieu, D., additional, Bocquet, A., additional, Bresson, J. L., additional, Briend, A., additional, Darmaun, D., additional, Frelut, M. L., additional, Ghisolfi, J., additional, Girardet, J. P., additional, Goulet, O., additional, Hankard, R., additional, Rieu, D., additional, Vidailhet, M., additional, and Turck, D., additional

Published
2011
Full Text
View/download PDF

191. Pentanucleotide repeats at the spinocerebellar ataxia type 31 (SCA31) locus in Caucasians

Author

Ishikawa, K., primary, Dürr, A., additional, Klopstock, T., additional, Müller, S., additional, De Toffol, B., additional, Vidailhet, M., additional, Vighetto, A., additional, Marelli, C., additional, Wichmann, H.-E., additional, Illig, T., additional, Niimi, Y., additional, Sato, N., additional, Amino, T., additional, Stevanin, G., additional, Brice, A., additional, and Mizusawa, H., additional

Published
2011
Full Text
View/download PDF

195. Lait de vache ou lait de croissance : quel lait recommander pour les enfants en bas âge (1–3 ans) ?

Author

Ghisolfi, J., primary, Vidailhet, M., additional, Fantino, M., additional, Bocquet, A., additional, Bresson, J.-L., additional, Briend, A., additional, Chouraqui, J.-P., additional, Darmaun, D., additional, Dupont, C., additional, Frelut, M.-L., additional, Girardet, J.-P., additional, Goulet, O., additional, Hankard, R., additional, Rieu, D., additional, and Turck, D., additional

Published
2011
Full Text
View/download PDF

196. Impaired saccadic adaptation in DYT11 dystonia

Author

Hubsch, C., primary, Vidailhet, M., additional, Rivaud-Pechoux, S., additional, Pouget, P., additional, Brochard, V., additional, Degos, B., additional, Pelisson, D., additional, Golmard, J.-L., additional, Gaymard, B., additional, and Roze, E., additional

Published
2011
Full Text
View/download PDF

197. A novel DCC mutation and genetic heterogeneity in congenital mirror movements

Author

Depienne, C., primary, Cincotta, M., additional, Billot, S., additional, Bouteiller, D., additional, Groppa, S., additional, Brochard, V., additional, Flamand, C., additional, Hubsch, C., additional, Meunier, S., additional, Giovannelli, F., additional, Klebe, S., additional, Corvol, J. C., additional, Vidailhet, M., additional, Brice, A., additional, and Roze, E., additional

Published
2011
Full Text
View/download PDF

199. Prise en charge diététique de l’allergie aux protéines du lait de vache

Author

Dupont, C., primary, Chouraqui, J.-P., additional, de Boissieu, D., additional, Bocquet, A., additional, Bresson, J.-L., additional, Briend, A., additional, Darmaun, D., additional, Frelut, M.-L., additional, Ghisolfi, J., additional, Girardet, J.-P., additional, Goulet, O., additional, Hankard, R., additional, Rieu, D., additional, Rigo, J., additional, Vidailhet, M., additional, and Turck, D., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results